Filda: Tadalafil Brand by Intas

Filda Product Facts at a Glance

The strongest current primary source is Intas Pharmaceuticals' own product portfolio. It lists FILDA with tadalafil 20 mg, places the product in the urology therapeutic segment and gives a pack detail of 4's.

A current Indian pharmacy listing independently identifies Filda 20 mg as tadalafil 20 mg and lists Intas Pharmaceuticals Ltd as marketer. Retail pack presentations can differ from the company portfolio entry, so pack size should be treated as a market attribute rather than the defining pharmaceutical identity.

Filda, Tadalafil and Intas Are Different Entity Levels

Filda is the commercial product name, tadalafil is the active pharmaceutical ingredient and Intas Pharmaceuticals is the company whose current portfolio lists the brand. These three terms describe related but different aspects of the product.

The distinction matters because Intas has a much broader pharmaceutical portfolio and tadalafil itself appears under many unrelated brands from other companies. Filda therefore identifies one particular tadalafil product relationship rather than another name for the drug molecule.

The broader company context belongs on the Intas tadalafil page rather than being expanded into a manufacturer profile here.

Why Filda 20 mg Is the Core Source-Backed Product

Intas's current company portfolio explicitly pairs the Filda brand with tadalafil 20 mg. That makes 20 mg the strongest product-specific strength to use when defining the brand on this page.

A current retail listing also documents Filda 10 mg with tadalafil 10 mg and Intas Pharmaceuticals as marketer. Because that additional strength is not shown in the current Intas portfolio entry used as our primary source, it is better treated as secondary market evidence rather than expanding the official company-backed strength statement.

This distinction allows the page to remain accurate without claiming either that Filda exists only at 20 mg or that every retailer-listed strength is part of the current official Intas portfolio.

The Intas Portfolio Lists Filda 20 mg as a Four-Unit Pack

The current Intas product table shows FILDA with the pack detail 4's. That is useful company-source evidence for the product presentation documented in Intas's portfolio.

Current retail records can show different pack quantities, which is not unusual in medicine distribution. For that reason, pack size should not be treated as permanently fixed in the same way as the product's active ingredient and source-backed strength.

When verifying Filda, brand name, tadalafil content, strength, company information and current package details should be considered together.

Intas Places Filda in Its Urology Portfolio

Intas's current product catalog categorizes Filda under Urology. That portfolio placement is useful company-level context because it shows how Intas groups the product within its Indian range without requiring this page to reproduce the company's entire urology business.

The same portfolio contains many other urology products with unrelated active ingredients, demonstrating that the therapeutic segment is broader than tadalafil alone. Filda remains the tadalafil-specific product entity relevant here.

The wider company and portfolio relationship is covered on Intas tadalafil.

Filda Is Documented as a Single-Ingredient Tadalafil Product

The current Intas portfolio lists Filda with tadalafil 20 mg as its active ingredient entry. It is therefore appropriate to treat Filda as a single-ingredient tadalafil product in this brand context.

Intas separately lists combination products containing tadalafil plus another active drug, such as DEJAC-T with dapoxetine and tadalafil. Keeping those products separate prevents a company portfolio from being mistaken for one Filda product family.

The Filda page therefore remains centered on the single-ingredient tadalafil entity rather than absorbing unrelated Intas combination products.

How Filda Fits the Branded-Generic Tadalafil Market

Filda can be described in Indian market terms as a branded tadalafil or branded-generic tadalafil product because the established active ingredient tadalafil is marketed under a proprietary product name. This terminology describes market identity rather than automatically establishing regulatory equivalence elsewhere.

In the United States, FDA approval and therapeutic-equivalence evaluations apply to exact drug products within the Orange Book framework. A Filda tablet containing tadalafil 20 mg cannot therefore be called an FDA-approved Cialis generic merely because it shares the active ingredient and nominal strength.

The broader regulatory distinction belongs on the generic tadalafil page.

Filda and Cialis Share Tadalafil but Are Different Products

Filda and Cialis can both contain tadalafil, and a Filda 20 mg tablet can match a Cialis 20 mg tablet at the nominal active-ingredient strength level. That does not make Filda and Cialis the same finished product.

Brand identity, company relationship, formulation details, regulatory application and bioequivalence evidence remain separate questions. A matching milligram amount establishes only one part of the product comparison.

The broader branded-versus-generic distinction belongs on tadalafil vs Cialis, allowing this page to remain focused on Filda.

Filda's Regulatory Context Depends on the Exact Market

The current sources used here establish Filda within Intas's Indian product portfolio and confirm an Indian marketed tadalafil presentation. They should not be treated as evidence that the Filda brand carries the same approval in the United States, European Union or another jurisdiction.

A pharmaceutical company can market different brands or approved generics in different countries, and regulatory status attaches to the exact finished product and application rather than to the company or active ingredient in isolation.

The safest description is therefore that Filda is a documented Intas tadalafil product in the Indian market context, without extending that statement into unverified cross-jurisdiction approval claims.

Filda 20 mg Is a Product Strength, Not a Universal Dose Recommendation

The 20 mg in Filda 20 describes the amount of tadalafil in the documented tablet. It should not be interpreted as a universal starting dose, a required dose or evidence that 20 mg is appropriate for every person or tadalafil indication.

Tadalafil dose and schedule depend on treatment context, other medicines, organ function and the authorized product instructions. Product strength and individualized dose selection are therefore separate questions.

General dosing frameworks belong on the tadalafil dosage guide.

Filda Product Identity Should Be Kept Separate From General Tadalafil Uses

Current Indian retail descriptions associate Filda tadalafil products with familiar clinical uses of tadalafil, but retailer summaries are not a substitute for an authoritative product label covering every Filda presentation and jurisdiction. General drug information should therefore not be silently converted into exact brand-specific regulatory claims.

This page anchors its strongest statements in what Intas directly documents: the Filda brand, tadalafil 20 mg, urology portfolio placement and pack detail. Broader tadalafil clinical contexts remain drug-level information unless product-specific authorized labeling establishes more.

This distinction keeps the page useful without overstating what the current Filda sources prove.

Filda Uses Tadalafil's PDE5 Pharmacology

Because Filda contains tadalafil, its active pharmacologic component is a phosphodiesterase type 5 inhibitor. PDE5 inhibition reduces degradation of cyclic GMP in tissues where nitric oxide-cGMP signaling is active.

That basic mechanism comes from tadalafil rather than from the Filda brand name. Branding changes the finished-product identity, not the molecular target of the active ingredient.

The pharmacologic pathway is covered in depth on how tadalafil works.

Filda Shares Tadalafil's Active-Ingredient Safety Context

Because Filda contains tadalafil, clinically important tadalafil contraindication and interaction principles are relevant to understanding the active drug. These include major blood-pressure interactions with nitrates and guanylate cyclase stimulators, together with other medicine- and patient-specific considerations.

Drug-level safety and exact product labeling should still remain distinct. A U.S. CIALIS label or another tadalafil product's prescribing information should not simply be presented as if it were the official Filda labeling.

Detailed active-ingredient safety belongs on tadalafil contraindications, tadalafil drug interactions and tadalafil side effects.

Filda Is One Product Within Intas's Wider Portfolio

Intas Pharmaceuticals has a broad domestic and international medicine portfolio across many therapeutic areas. Filda appears specifically within its Indian urology product list and should not be used as a synonym for the company's entire tadalafil or urology activity.

This page therefore uses company information only where it helps establish Filda's identity. Company-level tadalafil analysis belongs on the Intas tadalafil page, while cross-company brand discovery belongs on the Indian tadalafil brands hub.

Maintaining that boundary keeps Filda's product intent distinct from the manufacturer silo.

How to Verify a Filda Product Claim

A strong Filda claim should connect the brand name, tadalafil ingredient, strength and Intas relationship through a traceable source. Intas's current product portfolio does this directly for Filda 20 mg and also provides therapeutic-segment and pack information.

Established Indian pharmacy records can provide secondary confirmation of current marketed presentations and marketer information, but retail records can vary in pack size and may include product strengths not shown in the current company portfolio. Those differences should be described rather than silently reconciled.

Regulatory approval and therapeutic-equivalence claims require stronger jurisdiction-specific evidence and should not be inferred from retailer listings or matching ingredient strength.

Common Misunderstandings About Filda

Filda is sometimes described online as though it were simply another name for Cialis or tadalafil. Filda contains tadalafil, but the brand remains a separate finished-product identity associated with Intas Pharmaceuticals.

A second mistake is to treat the 20 mg company-catalog entry as proof that Filda exists only in one strength or that 20 mg is the appropriate dose for every user. Current secondary market records show other presentations, while dose selection is a separate clinical question.

Finally, matching tadalafil 20 mg does not by itself establish FDA approval, bioequivalence or therapeutic equivalence to a U.S. Cialis or generic tadalafil product.

Key Takeaways: Filda

Filda is a branded tadalafil product associated with Intas Pharmaceuticals. Intas's current product portfolio directly lists FILDA with tadalafil 20 mg in the urology segment and gives a four-unit pack detail, making Filda 20 mg the strongest primary-source-backed product presentation.

Current secondary Indian market records also document other Filda presentations, including 10 mg, but those records do not replace the current Intas portfolio as the primary source for this page. The distinction allows the brand to be described accurately without claiming either an artificially narrow or unsupported broad official strength range.

Filda's tadalafil ingredient and nominal strength do not by themselves establish FDA approval or therapeutic equivalence to Cialis or another tadalafil product. Brand identity, company relationship and regulatory status must be evaluated separately for the exact finished product and jurisdiction.